TrialBMC cancer2022

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.

Patrick Schöffski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.